Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
about
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactamsRandomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.Ceftazidime for neutropenic fevers: is it still an appropriate choice?Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes.European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in LeukemiaGuidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit.Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk PatientsEvidence-based guidelines for empirical therapy of neutropenic fever in Korea.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).An update on emerging therapies for urinary tract infections.The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey.Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies.Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.C-reactive protein and fever in neutropenic patients.Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer.Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.Micro-organisms Associated with Febrile Neutropenia in Patients with Haematological Malignancies in a Tertiary Care Hospital in Eastern India.Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality.
P2860
Q24236653-FC960BF0-C0A6-4AD3-8518-717D8BFBC45CQ31918096-42D8B2F4-5A39-4F14-9949-F2B4A3826CAAQ33886119-1BD8B5C4-7766-459B-92B5-784270C4E2D0Q33964258-949058AE-AF64-43A9-B6D8-EC8AAED2A042Q34390823-30AC8609-89B5-4F0B-A363-BA108673E334Q34589960-FCB0DC0F-A0F2-4EED-BA0D-92F4B2302155Q34673367-7CA38C73-8D48-49C2-896C-10759AA6DE5EQ35033597-AF1D26B3-F434-4C54-A9AB-A9914C2C61F4Q37377897-0E49D82E-C58F-4F7D-8757-F2D7C288875FQ38751454-1DDED719-D4D3-44BA-8FFC-B31A80AF12BEQ40111888-B2F1AC7E-2C37-47B5-855A-292F8B3F0AF0Q40352823-C2173735-426D-472C-9E3B-3A357B659B73Q40364811-AE1F9311-B945-4438-9589-4F6F687BD263Q40393915-13C45A47-C82D-484C-9CE8-D0D893852AA0Q40433361-8067ED1B-721F-46BA-8AA7-720A511A358BQ40462342-FE2E4D04-30AC-4CB9-AC5A-6CA291EC95BCQ40512932-D92D2151-DEC7-4D31-89AB-CC9A197F8803Q40525696-C9D3505F-B62C-4B89-A80F-24618320837CQ40591496-BCC078E9-F79B-487B-BD13-49D04E7FFB66Q40593575-DEB7F571-B6D0-4B0B-8147-5E283245ED40Q40605985-C52328B9-24AF-4485-872C-59A00E794916Q40612821-B52AB45C-023D-44EA-A0AA-9BBC17342D3DQ40615385-08757598-A870-4509-A091-486ED2FC57D8Q40624011-794F22B1-D4B7-4D67-9328-E683940B5E70Q40812219-1321368A-1968-4C55-9DB0-B43640FDAC30Q41576635-A09EBB89-ECE4-4103-B954-BCE87D45FC1EQ53556450-9B5C498E-52F4-4CE7-9046-627D19FCF0C2
P2860
Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@ast
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@en
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@nl
type
label
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@ast
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@en
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@nl
prefLabel
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@ast
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@en
Cefepime/amikacin versus cefta ...... e French Cefepime Study Group.
@nl
P2093
P356
P1476
Cefepime/amikacin versus cefta ...... he French Cefepime Study Group
@en
P2093
C Cordonnier
M Gardembas
P356
10.1093/CLINIDS/24.1.41
P407
P577
1997-01-01T00:00:00Z